Sanofi shares plunge on Acomplia rejection

An FDA expert panel unanimously rejected Sanofi-Aventis' Acomplia, its would-be obesity blockbuster, out of concerns regarding the drug's potential side effects. And analysts are concerned that the fallout from that vote could put a big dent in the pharma company's efforts to market the drug in Europe. Some analysts are anticipating a tougher label for the drug in Europe.

The FDA panel was primarily concerned that Acomplia increased incidents of suicidal behavior and depression among patients. That's likely to play a major role in influencing the agency's final decision on Acomplia. It wasn't a big leap for investors to make. They sent shares of Sanofi down 8 percent on the news.

- see the release on the FDA' s decision
- read the Dow Jones report

Related Articles:
Sanofi shares slide as FDA delays Acomplia-again. Report
Sanofi shares slip on Acomplia delay. Report
Delays forecasted for blockbuster obesity drug. Report

Suggested Articles

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.